A01K 2217/077
Heterozygous knock out animals displaying phenotype
Official title: heterozygous knock out animals displaying phenotype
A01K2217/077 (Heterozygous knock out animals displaying phenotype) appears on 43 US grants and 109 published applications in this corpus.
Search patents in A01K- Granted patents
- 43
- Published applications
- 109
- Assignees
- 83
- Inventors
- 273
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2008 | 0 | 1 |
| 2009 | 0 | 1 |
| 2010 | 0 | 2 |
| 2011 | 0 | 5 |
| 2012 | 1 | 3 |
| 2013 | 1 | 1 |
| 2014 | 2 | 3 |
| 2015 | 0 | 5 |
| 2016 | 0 | 8 |
| 2017 | 3 | 5 |
| 2018 | 5 | 6 |
| 2019 | 4 | 9 |
| 2020 | 2 | 8 |
| 2021 | 3 | 8 |
| 2022 | 1 | 14 |
| 2023 | 7 | 18 |
| 2024 | 7 | 6 |
| 2025 | 5 | 4 |
| 2026 | 2 | 2 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Targeted RNA degradation allows precision repurposing of protein-targeted small molecule medicines to RNA11 Aug 2026US 12,702,715 B2University of Florida Research Foundation, Inc.
- Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathies19 May 2026US 12,630,827 B2RogCon, Inc.
- Transgenic animal phenotyping platform and uses thereof18 Nov 2025US 12,471,580 B2InVivo Biosystems, Inc.
- Composition for preventing or treating benign tumor14 Oct 2025US 12,440,546 B2International Institute of Cancer Immunology, Inc.
- Compositions and methods for treating laminopathies15 Jul 2025US 12,357,707 B2Encoded Therapeutics, Inc.
- Transgenic animals and recombinant host cells comprising specific gene variants and methods of creating same14 May 2026US 2026/0130347 A1
- Bag3 methods and uses for treatment of inflammation1 Jan 2026US 2026/0000789 A1Loyola University of Chicago
- Compositions and methods for treating diabetic cardiomyopathy18 Dec 2025US 2025/0381306 A1University of Utah Research Foundation
- Transgenic animal phenotyping platform and uses thereof16 Oct 2025US 2025/0318509 A1InVivo Biosystems, Inc.
- Gene therapy for haploinsufficiency17 Jul 2025US 2025/0228980 A1The Regents of the University of California
Most cited
By later US patents
- Chimaeric surrogate light chains (SLC) comprising human VpreB13US 9,963,716 B2Kymab Limited · 2018
- Domain 5 of CD163 for use in antiviral compositions against PRRS, and transgenic animals5US 9,854,790 B2The University Court of the University of Edinburgh · 2018
- Modulation and detection of a neuronal alternative splicing regulatory network for treatment and diagnosis of neurological disorders1US 10,772,928 B2Sinai Health System · 2020
- Genetically modified non-human animal with human or chimeric CD3e1US 10,945,420 B2Biocytogen JiangSu Co., Ltd. · 2021
- Tumor specific antibody conjugates and uses therefor1US 11,554,181 B2OncoTAb, Inc. · 2023